A Prospective, Multi-Center, Randomized Control Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 27
- 试验地点
- 7
- 主要终点
- Progression-Free Survival (PFS)
研究概览
简要总结
The purpose of this study is to determine whether ERCC1(excision repair cross-complementation 1 ) expression has effects on platinum-based chemotherapy for patients with locally advanced or metastatic gastric cancer, and to explore if ERCC1 can act as a biological predictor for the individual therapy of gastric cancer
详细描述
This is a prospective, multi-center, randomized control clinical trial, aimed to demonstrate if ERCC1 expression could predict the efficacy of platinum-based chemotherapy in patients with locally advanced or metastatic gastric cancer. A total of 180 patients are planned to be enrolled into the study. ERCC1 protein expression in paraffin-embedding tumor tissue is examined by immunohistochemistry (IHC). Patients with low ERCC1 expression (group L) will be treated with XP regimen. Patients with high ERCC1 expression will be randomized into group H-A or group H-B, and be treated with XP or DX regimen, respectively. The primary end point is progression free survival (PFS), and the secondary end points include the median overall survival, objective response rate (ORR),disease control rate(DCR), duration of response, safety(number and degree of adverse events), and the quality of life (QOL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18y≤Age≤65y, male or female
- •Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable locally advanced or recurrent and/or metastatic disease
- •At least one measurable lesion, according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1), assessed using imaging techniques (CT or MRI)
- •No prior anti-tumor treatment or an interval of at least 6 months from the last adjuvant chemotherapy, and an interval of at least 4 weeks from the last radical radiation therapy
- •No major organ disorder, with normal liver, kidney and heart function
- •Laboratory test must meet the following criteria: hemoglobin (HGB) ≥90g/L, neutrophil count ≥1.5×109/L, platelet count ≥100×109/L, creatinine clearance rate (CCr) ≥60ml/min, total bilirubin (TBil) ≤1.5 upper normal limitation (UNL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 UNL (For patients with liver metastasis, the AST/ALT must be ≤5.0 UNL), blood glucose ≤11.1 mmol/L
- •Life expectancy of at least 12 weeks
- •Signed informed consent
- •For women with child bearing potential, a negative serum or urine pregnancy test result should be obtained before enrollment
排除标准
- •Progression from prior palliative treatment with capecitabine- or docetaxel-based regimen
- •Serious uncontrolled systemic illness or medical condition: congestive heart failure, unstable angina, history of documented myocardial infarction within 6 months, uncontrolled hypertension and high risk uncontrollable arrhythmias; Obvious neurological or mental abnormalities including mental disorder, epileptic dementia, which affect compliance; Uncontrolled acute infections; Uncontrolled peptic ulcer, diabetes or other contraindication for corticosteroid therapy
- •Inability to take or absorb oral medicine
- •Concurrent administration of any other investigational drug, or have been enrolled in other clinical trial with investigational drug treatment within the 30 days of start of study treatment
- •Presence of neuropathy ≥grade 1 according to NCI-CTCAE V4.0
- •Hypersensitivity or known or suspicious allergic to any of the study drugs
- •Pregnant or lactated women
- •Unsuitable for the study or other chemotherapy determined by investigator
研究组 & 干预措施
H-A: ERCC1 High Expression Group A
XP：Capecitabine+Cisplatin
干预措施: Capecitabine+Cisplatin (Drug)
H-B: ERCC1 High Expression Group B
DX：Docetaxel+Capecitabine
干预措施: Docetaxel+Capecitabine (Drug)
L: ERCC1 Low Expression Group
XP：Capecitabine+Cisplatin
干预措施: Capecitabine+Cisplatin (Drug)
结局指标
主要结局
Progression-Free Survival (PFS)
时间窗: 2 years
次要结局
- Objective Response Rate(ORR),Including Complete Response(CR) and Partial Response(PR)(2 years)
- Disease Control Rate(DCR), Including Complete Response(CR) , Partial Response(PR) and Stable Disease(SD)(2 years)
- Duration of Response(2 years)
- Safety(number and degree of adverse events)(2 years)
- Quality of Life(QOL)(2 years)
- Overall Survival(OS)(2 years)
研究者
Yunpeng Liu
MD.,PhD
China Medical University, China